SAM #RRPV-HPAD

RFI for High Performance Immunoassay Antigen Diagnostics Technologies

The Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), BARDA Division Contracts Management & Acquisition, is seeking information from industry regarding high performance immunoassay technologies for antigen diagnostics in near-patient settings. - Government Buyer: - Department of Health and Human Services (HHS) - Office of the Assistant Secretary for Preparedness and Response (ASPR) - BARDA Division Contracts Management & Acquisition - OEMs and Vendors: - No specific OEMs or vendors are named in the solicitation - Products/Services Requested: - High performance immunoassay technologies for antigen testing - Focus on solutions with improved analytical sensitivity and multiplexing capabilities - No specific products, part numbers, or quantities provided - Unique/Notable Requirements: - Technologies must be suitable for near-patient settings - Emphasis on enhanced clinical utility for early infection detection and syndromic panels - Interest in both current and next-generation diagnostic solutions - The RFI is intended to gather information on the research and product landscape, not to procure specific items at this stage.

Description

“High Performance Antigen Diagnostics” Request for Information (RFI) Purpose The Rapid Response Partnership Vehicle (RRPV) is issuing this Request for Information (RFI) to better understand the research, development, and product landscape of current and next-generation high performance immunoassay technologies suitable for antigen testing in near-patient settings. While conventional antigen-based immunoassays offer speed, ease of use, and low cost, they remain limited by lower analytical sensitivity and limited multiplexing capability compared to nucleic acid amplification tests (NAATs), limiting their clinical utility, particularly for early infections and syndromic panels.

View original listing